(Q36732580)

16 August 2017

1 reference

title

Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation (English)

1 reference

post-transplant lymphoproliferative disorder

16 August 2017

main subject

0 references

organ transplantation

1 reference

Nicolaas A Bakker

1

1 reference

16 August 2017

Gustaaf W van Imhoff

series ordinal

2

1 reference

16 August 2017

Erik A M Verschuuren

series ordinal

3

1 reference

16 August 2017

Willem J van Son

series ordinal

4

1 reference

16 August 2017

language of work or name

1 reference

1 March 2007

1 reference

16 August 2017

published in

Transplant International

1 reference

16 August 2017

volume

20

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

207-218

1 reference

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Early onset post-transplant lymphoproliferative disease is associated with allograft localization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Posttransplant primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Treatment of PTLD with rituximab or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Role of fine-needle aspiration in the clinical management of solid organ transplant recipients: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Post-transplant lymphoproliferative disease: association with induction therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Rapid occurrence of lymphoproliferative disease after pancreas-kidney transplantation performed during acute primary Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Polyomavirus-associated nephropathy: update on BK virus-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Lymphoproliferative disorders in Oxford renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Posttransplant lymphoproliferative disorders presenting at sites of previous surgical intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Lymphoproliferative disorders after lung transplantation: imaging features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Orbital presentation of posttransplantation lymphoproliferative disorder: a small case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Real-time polymerase chain reaction (RQ-PCR) for the monitoring of Epstein-Barr virus (EBV) load in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

PTLD visualization by FDG-PET: improved detection of extranodal localizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

Lymphomas occurring late after solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00416.X

10.1111/J.1432-2277.2006.00416.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference